An interventional study of Medium Cut-Off Dialyzer for Expanded Hemodialysis in End Stage Kidney Disease (ESKD), sponsored by Mackay Memorial Hospital. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Mackay Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Kidney Failure, Chronic with a site in Taiwan — 11 open to participants now, 13 under way, 2 of them phase 3. Kidney Failure, Chronic · Taiwan.
Among the 70 studies in Kidney Failure, Chronic with a site in Taiwan, this one is the 51st largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2024, is one of 25 with no phase, and was the 70th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →11 of the 70 studies in Kidney Failure, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei City Hospital · Sites in Taiwan
Ages 18+
Singulera Therapeutics Inc. · Sites in Taiwan, United States
Ages 18–65
CSL Behring · Sites in Taiwan, United States, Argentina and 32 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 10 · Phase 4 13
First in 2004; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 52 interventional studies, 94 across the 16 observational. Of the 31 that completed or were terminated, 9 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 70 have an industry lead sponsor. The 10 most frequent:
Mackay Memorial Hospital is the lead sponsor of 119 studies on the registry; 27 are open to participants now.
Mackay Memorial Hospital has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies in Kidney Failure, Chronic with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06980922Chang Gung Memorial HospitalThe Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension | 2027-05-31 |
| NCT07794826Far Eastern Memorial HospitalEfficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 70 studies in Kidney Failure, Chronic with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Expanded hemodialysis (HDx) is a dialysis treatment designed to improve the removal of certain waste products from the blood. However, its effects on health-related quality of life and blood levels of uremic toxins in patients receiving long-term hemodialysis remain uncertain.
This study aimed to evaluate changes in quality of life and uremic toxin levels after switching from conventional hemodialysis to HDx. Patients who had been receiving maintenance hemodialysis for at least 10 years underwent HDx for three months. Quality of life and blood levels of selected uremic toxins were assessed before and after the treatment period.
The study aimed to determine whether switching to HDx was associated with changes in patients' quality of life and uremic toxin profiles.
This was a single-center, single-arm, before-and-after study evaluating the effects of expanded hemodialysis (HDx) on health-related quality of life and uremic toxin profiles in patients undergoing long-term maintenance hemodialysis.
Eligible participants were adults who had received maintenance hemodialysis three times weekly for at least 10 years. Participants were switched from conventional hemodialysis to HDx using a medium cut-off dialyzer for three months.
Health-related quality of life was assessed at baseline and after three months using the RAND 36-Item Health Survey (RAND-36). Blood samples were collected at both time points to evaluate selected middle-molecule biomarkers and protein-bound uremic toxins, including beta-2 microglobulin, free light chains, indoxyl sulfate, and p-cresyl sulfate. Additional laboratory and dialysis adequacy parameters were also evaluated.
Changes between baseline and three months were analyzed using paired statistical comparisons. As this was a single-arm study without a concurrent control group, the findings were intended to describe changes associated with switching to HDx rather than establish a causal treatment effect.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving long-term maintenance hemodialysis were switched from conventional hemodialysis to expanded hemodialysis (HDx) using a medium cut-off dialyzer for three months. Hemodialysis was performed three times weekly. Health-related quality of life and uremic toxin levels were assessed at baseline and after the three-month HDx intervention.
Device: Medium Cut-Off Dialyzer for Expanded Hemodialysis
Participants were switched from conventional maintenance hemodialysis to expanded hemodialysis (HDx) using a medium cut-off (MCO) dialyzer for three months. Hemodialysis was performed three times weekly, with treatment sessions lasting 180-240 minutes, blood flow rates of 200-300 mL/min, and a dialysate flow rate of 500 mL/min. Dialysis prescriptions were adjusted according to individual clinical needs. Health-related quality of life and uremic toxin profiles were assessed before and after the three-month intervention.
Change in Health-Related Quality of Life Measured by RAND-36
Health-related quality of life was assessed using the RAND 36-Item Health Survey 1.0 (RAND-36) at baseline and after three months of expanded hemodialysis. The questionnaire evaluates eight health domains: physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, bodily pain, and general health. Each domain is scored from 0 to 100, with higher scores indicating better health status. Changes from baseline to three months were assessed for each domain separately. No overall composite score was calculated.
Time frame: Baseline and Month 3
Change in Intact Parathyroid Hormone Concentration
Time frame: Baseline and Month 3
Change in Beta-2 Microglobulin Concentration
Time frame: Baseline and Month 3
Change in Interleukin-6 Concentration
Time frame: Baseline and Month 3
Change in Kappa Free Light Chain Concentration
Time frame: Baseline and Month 3
Change in Lambda Free Light Chain Concentration
Time frame: Baseline and Month 3
Change in Total Indoxyl Sulfate Concentration
Time frame: Baseline and Month 3
Change in Free Indoxyl Sulfate Concentration
Time frame: Baseline and Month 3
Change in Total p-Cresyl Sulfate Concentration
Time frame: Baseline and Month 3
Change in Free p-Cresyl Sulfate Concentration
Time frame: Baseline and Month 3
Plan to share: No — Individual participant data will not be shared with external researchers because the study involves sensitive patient-level clinical information and no external individual participant data sharing is planned under the current study protocol.
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Jun 2024, 3 months.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 3 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.